1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B1F9D9BF97A471C985256F9D00635A8B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/timing-structuring-and-staffing-for-drug-delivery-system-development?opendocument
18
19opendocument
2035.173.234.140
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Optimizing Product Portfolio Lifecycle Management

Timing, Structuring and Staffing for Drug Delivery System Development

DB Image

ID: 4782


Features:

Metrics, Graphics


Pages/Slides: 45


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

As there are more me-too drugs crowding the marketplace, it is becoming critical to differentiate products through new formulations and delivery methods. To create these necessary new systems, leading companies are re-orienting or refining their development cycles as well as their approaches to lifecycle management.

Leaders in development, both in marketing and R&D, will benefit from this presentation by comparing their own approaches to this area of development to other companies, some of which are leading the way in organizing and resourcing this area. For example, executives can learn when in the clinical trial process companies begin to develop and market drug delivery systems.


Key Topics

  • Functional group input on drug delivery system development by phase
  • Marketing roles & responsibilities
  • Marketing activities and entry point
  • Key activities impact rating
  • Marketing staffing levels
  • Marketing budget levels
  • Branding and patent protection

Key Findings
A key finding from the research is that 75% of companies studied employ a centralized group structure to manage the development of the new product delivery system. However, of these companies, 75% do not dedicate marketing staff to the support of the drug delivery development process.

Methodology
This research was conducted under Best Practices LLC's Business Excellence Board membership research service.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
Amgen; Vital Therapies; Bayer; Theratechnologies; DSM Pharmaceutical; Eli Lilly; Procter & Gamble Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.